Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome–associated Sos1 mutation.
暂无分享,去创建一个
J. Seidman | R. Kucherlapati | B. Neel | R. Bronson | Peng-Chieh Chen | C. Seidman | H. Wakimoto | A. Roberts | T. Araki | D. Conner | Tao Yuan
[1] Randhir Singh,et al. Molecular targets and regulators of cardiac hypertrophy. , 2010, Pharmacological research.
[2] M. Geletu,et al. Activated Rac1 requires gp130 for Stat3 activation, cell proliferation and migration. , 2010, Experimental cell research.
[3] J. Molkentin,et al. Extracellular signal‐regulated kinase 1/2 (ERK1/2) signaling in cardiac hypertrophy , 2010, Annals of the New York Academy of Sciences.
[4] Rony Seger,et al. The subcellular localization of MEK and ERK—A novel nuclear translocation signal (NTS) paves a way to the nucleus , 2010, Molecular and Cellular Endocrinology.
[5] H. Hasle. Malignant Diseases in Noonan Syndrome and Related Disorders , 2009, Hormone Research in Paediatrics.
[6] J. Schmitt,et al. Cardiac hypertrophy: targeting Raf/MEK/ERK1/2-signaling. , 2009, The international journal of biochemistry & cell biology.
[7] Tomoki Nakamura,et al. Noonan syndrome is associated with enhanced pERK activity, the repression of which can prevent craniofacial malformations , 2009, Proceedings of the National Academy of Sciences.
[8] Ravi Iyengar,et al. Mutation in SHOC2 promotes aberrant protein N-myristoylation and underlies Noonan-like syndrome with loose anagen hair , 2009, Nature Genetics.
[9] Tomoki Nakamura,et al. Protein tyrosine phosphatase activity in the neural crest is essential for normal heart and skull development , 2009, Proceedings of the National Academy of Sciences.
[10] Xin-Yuan Fu,et al. Negative Regulation of Stat3 by Activating PTPN11 Mutants Contributes to the Pathogenesis of Noonan Syndrome and Juvenile Myelomonocytic Leukemia* , 2009, The Journal of Biological Chemistry.
[11] K. Rauen,et al. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. , 2009, Current opinion in genetics & development.
[12] Susan A. Elmore,et al. Histology Atlas of the Developing Mouse Heart with Emphasis on E11.5 to E18.5 , 2009, Toxicologic pathology.
[13] B. Neel,et al. Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation , 2009, Proceedings of the National Academy of Sciences.
[14] J. Molkentin,et al. Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome , 2008, Proceedings of the National Academy of Sciences.
[15] Anthony J. Muslin,et al. MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. , 2008, Clinical science.
[16] T. Zimmers,et al. Body surface area prediction in normal, hypermuscular, and obese mice. , 2008, The Journal of surgical research.
[17] K. Kuo,et al. Angiotensin II Activates Signal Transducer and Activators of Transcription 3 via Rac1 in Atrial Myocytes and Fibroblasts: Implication for the Therapeutic Effect of Statin in Atrial Structural Remodeling , 2008, Circulation.
[18] P. Cohen,et al. The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.
[19] G. Dorn,et al. Mediating ERK 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome. , 2007, The Journal of clinical investigation.
[20] Michael J Ackerman,et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy , 2007, Nature Genetics.
[21] Suzanne Schubbert,et al. Hyperactive Ras in developmental disorders and cancer , 2007, Nature Reviews Cancer.
[22] Kenichi Nomoto,et al. Recent advances of MEK inhibitors and their clinical progress. , 2007, Current topics in medicinal chemistry.
[23] D. Hilfiker-Kleiner,et al. Survival pathways in hypertrophy and heart failure: The gp130-STAT3 axis , 2007, Basic Research in Cardiology.
[24] J. Settleman,et al. GEFs in growth factor signaling , 2007, Growth factors.
[25] Wendy Schackwitz,et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome , 2006, Nature Genetics.
[26] D. Kwiatkowski,et al. Requirement of Rac1 in the development of cardiac hypertrophy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[27] Kam Y. J. Zhang,et al. Germline KRAS mutations cause Noonan syndrome , 2006, Nature Genetics.
[28] J. Lyons,et al. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. , 2005, Current opinion in pharmacology.
[29] F. McCormick,et al. Killing time for cancer cells , 2005, Nature Reviews Cancer.
[30] C. Der,et al. GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors , 2005, Nature Reviews Molecular Cell Biology.
[31] M. Kotlikoff,et al. Gene trap and gene inversion methods for conditional gene inactivation in the mouse , 2005, Nucleic acids research.
[32] J. Sebolt-Leopold,et al. Targeting the mitogen-activated protein kinase cascade to treat cancer , 2004, Nature Reviews Cancer.
[33] D. Gilliland,et al. Mouse model of Noonan syndrome reveals cell type– and gene dosage–dependent effects of Ptpn11 mutation , 2004, Nature Medicine.
[34] Hua Yu,et al. The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.
[35] P. Goldschmidt-Clermont,et al. Rac regulates cardiovascular superoxide through diverse molecular interactions: more than a binary GTP switch. , 2003, American journal of physiology. Cell physiology.
[36] M. Hori,et al. The Small GTP-binding Protein Rac1 Induces Cardiac Myocyte Hypertrophy through the Activation of Apoptosis Signal-regulating Kinase 1 and Nuclear Factor-κB* , 2003, Journal of Biological Chemistry.
[37] S. Meloche,et al. Rho Family GTPases Are Required for Activation of Jak/STAT Signaling by G Protein-Coupled Receptors , 2003, Molecular and Cellular Biology.
[38] Jian-Mei Li,et al. Fluvastatin Enhances the Inhibitory Effects of a Selective Angiotensin II Type 1 Receptor Blocker, Valsartan, on Vascular Neointimal Formation , 2003, Circulation.
[39] G. Booz,et al. Interplay between the cardiac renin angiotensin system and JAK-STAT signaling: role in cardiac hypertrophy, ischemia/reperfusion dysfunction, and heart failure. , 2002, Journal of molecular and cellular cardiology.
[40] D. Bar-Sagi,et al. The Two Hats of SOS , 2002, Science's STKE.
[41] Giorgio Scita,et al. Mechanisms through which Sos-1 coordinates the activation of Ras and Rac , 2002, The Journal of cell biology.
[42] Michael A. Patton,et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome , 2001, Nature Genetics.
[43] D. Bar-Sagi,et al. Rac1 mediates STAT3 activation by autocrine IL-6 , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[44] D. Bar-Sagi,et al. Ras and Rho GTPases A Family Reunion , 2000, Cell.
[45] H. Vikis,et al. Regulation of STAT3 by direct binding to the Rac1 GTPase. , 2000, Science.
[46] M. Siddiqui,et al. The role of Jak/STAT signaling in heart tissue renin-angiotensin system , 2000, Molecular and Cellular Biochemistry.
[47] G. Scita,et al. Signaling from Ras to Rac and beyond: not just a matter of GEFs , 2000, The EMBO journal.
[48] A. Clerk,et al. Small guanine nucleotide-binding proteins and myocardial hypertrophy. , 2000, Circulation research.
[49] T. Hewett,et al. Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1. , 2000, The Journal of clinical investigation.
[50] H. Rossbach,et al. Duchenne muscular dystrophy and concomitant metastatic alveolar rhabdomyosarcoma. , 1999, Journal of pediatric hematology/oncology.
[51] E. Mantadakis,et al. Prevalence of priapism in children and adolescents with sickle cell anemia. , 1999, Journal of pediatric hematology/oncology.
[52] K. Tanaka,et al. A requirement for the rac1 GTPase in the signal transduction pathway leading to cardiac myocyte hypertrophy. , 1998, The Journal of clinical investigation.
[53] S. Ogawa,et al. Biphasic activation of the JAK/STAT pathway by angiotensin II in rat cardiomyocytes. , 1998, Circulation research.
[54] D. Bar-Sagi,et al. Coupling of Ras and Rac guanosine triphosphatases through the Ras exchanger Sos. , 1998, Science.
[55] S. Ogawa,et al. Role of angiotensin II in activation of the JAK/STAT pathway induced by acute pressure overload in the rat heart. , 1997, Circulation research.
[56] F. Alt,et al. Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[57] B. Berk,et al. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor , 1995, Nature.
[58] D. Horn,et al. A restricted spectrum of NRAS mutations causes Noonan syndrome , 2010, Nature Genetics.
[59] Ravi Iyengar,et al. Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair , 2009 .
[60] J. Sebolt-Leopold,et al. Targeting MEK is effective chemoprevention of hepatocellular carcinoma in TGF-alpha-transgenic mice. , 2008, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract.
[61] Li Li,et al. Germline gain-of-function mutations in SOS1 cause Noonan syndrome , 2007, Nature Genetics.
[62] J. Sebolt-Leopold,et al. Targeting MEK is Effective Chemoprevention of Hepatocellular Carcinoma in TGF-α-Transgenic Mice , 2007, Journal of Gastrointestinal Surgery.
[63] Michiko Furutani,et al. Germline gain-of-function mutations in RAF1 cause Noonan syndrome , 2007, Nature Genetics.
[64] D. Hilfiker-Kleiner,et al. Survival pathways in hypertrophy and heart failure: The gp130-STAT3 axis , 2007, Basic Research in Cardiology.
[65] A. Brice,et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome , 2002, Nature Genetics.
[66] M. Arıcı,et al. A unifying hypothesis for the renin-angiotensin system and hematopoiesis: sticking the pieces together with the JAK-STAT pathway. , 2000, Medical hypotheses.
[67] J B Gibbs,et al. Anticancer drug targets: growth factors and growth factor signaling. , 2000, The Journal of clinical investigation.
[68] D. Chitayat,et al. Juvenile myelomonocytic leukemia and Noonan syndrome. , 1999, Journal of pediatric hematology/oncology.
[69] G. J. Bhat,et al. Cross-talk between angiotensin II and interleukin-6-induced signaling through Stat3 transcription factor , 1998, Basic Research in Cardiology.